Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.
Electromed, Inc. (NYSE MKT: ELMD) is a Minnesota-based company recognized as an innovative leader in the development, manufacture, and worldwide distribution of the SmartVest® Airway Clearance System. This patented system leverages High-Frequency Chest Wall Oscillation (HFCWO), offering a well-tolerated alternative to traditional chest physiotherapy (CPT). The system is designed to deliver effective and comfortable airway clearance treatment for patients suffering from the consequences of retained secretions.
Clinically proven, HFCWO technology helps clear the lungs of excess mucus, thereby improving lung function and reducing infections for individuals with conditions such as atelectasis, COPD, bronchiectasis, neuromuscular diseases, and cystic fibrosis. Electromed, Inc. is accredited by the Joint Commission and holds ISO 13485:2003 and ISO 9001:2008 certifications, demonstrating their commitment to quality and safety.
The SmartVest System consists of a programmable air pulse generator, a therapy garment worn over the upper body, and a connecting hose. Together, these components provide a safe, comfortable, and effective airway clearance therapy that enhances the quality of life for patients with compromised pulmonary function.
Electromed, Inc. continuously strives for excellence and compassionate service. Their products are designed with patient comfort and usability in mind, ensuring that users receive the best possible care. With a global reach, the company is dedicated to improving respiratory health for patients worldwide.
Stay updated with the latest developments, achievements, and financial performance of Electromed, Inc. by following their news and updates. The company's ongoing projects and partnerships underscore its commitment to innovation and excellence in the field of airway clearance therapy.
Electromed, Inc. (AMEX: ELMD) will release its fiscal 2022 Q1 financial results on November 9, 2021, after market close. A conference call will follow at 5:00 p.m. Eastern Time to discuss these results. Interested parties can join via phone or through a live webcast available on the company’s website. Electromed is known for its innovative airway clearance technologies, particularly the SmartVest Airway Clearance System, catering to patients with compromised pulmonary function.
Electromed, Inc. (NYSE: ELMD) has announced a cooperation agreement with Summers Value Partners, which holds 5.9% of its stock, leading to the nomination of two new independent directors, Kathy Tune and Joe Galatowitsch, for the upcoming Fiscal 2022 Annual Meeting. A new Finance and Strategy Committee will be formed to enhance value creation. Retiring board members Steve Craney and George Winn will leave their positions. The company highlighted its commitment to growth, showcasing a strategy that aims for double-digit revenue growth and profitability.
Electromed, Inc. (AMEX: ELMD) has announced that its President and CEO, Kathleen Skarvan, along with CFO Mike MacCourt, will participate in the 2021 Colliers Institutional Investor Conference on September 9, 2021. The conference will be held virtually, highlighting the company’s commitment to engaging with investors and stakeholders. Electromed specializes in airway clearance technologies, notably the SmartVest® Airway Clearance System, to assist patients with compromised pulmonary function. The company is based in New Prague, Minnesota, and has been operational since 1992.
Electromed reported strong Q4 FY 2021 results, with a net revenue increase of 37.7% to $9.5 million, driven by a 90.6% growth in institutional sales and 33.6% in home care. Despite revenue growth, operating income fell to $0.7 million from $1.3 million in Q4 FY 2020, affected by past government stimulus and increased SG&A expenses. For FY 2021, total revenue rose 10.1% to $35.8 million but net income declined to $2.4 million, or $0.27 per diluted share. Cash reserves were $11.9 million, bolstered by $3.1 million in operating cash flow.
Electromed (NYSE American: ELMD) announced that it will release its fiscal 2021 fourth quarter financial results on August 24, 2021, post-market close. A conference call will follow at 5:00 PM ET to discuss the results. Participants can join via domestic and international dialing or through a live webcast available on the Investor Relations section of their website. The company specializes in airway clearance therapy products, including the SmartVest Airway Clearance System, supporting patients with compromised pulmonary function.
Electromed (NYSE American: ELMD) announced that Summers Value Partners intends to nominate four candidates for election to the Board of Directors at the upcoming Fiscal 2022 Annual Meeting of Shareholders. The Board is currently engaged in discussions with Summers Value Partners to evaluate the nominees, focusing on shareholder interests. With insiders owning over 16% of Electromed's shares, their interests align closely with those of the shareholders. A proxy statement detailing the Board's recommendations will be filed with the SEC and distributed to eligible shareholders.
Electromed, Inc. (NYSE American: ELMD) announced preliminary Q4 FY 2021 financial results, projecting net revenue of $9.3 to $9.5 million, a 37% increase from $6.9 million in Q4 FY 2020. Operating income is expected to be between $0.5 and $0.7 million, down from $1.3 million the previous year, which included $0.9 million from government stimulus. The company reported $11.9 million in cash with no debt. Management indicated that a recent data security incident did not materially impact financial results for the quarter, affirming strong performance despite pandemic challenges.
Electromed, a leader in airway clearance technologies (NYSE American: ELMD), announced participation in Canaccord Genuity’s 41st Annual Growth Conference, scheduled for August 10-12, 2021. The group presentation will take place on August 11, 2021, at 10:00 AM Eastern Time. Attendees can access the webcast through a link provided in the press release or via the Investor Relations section of Electromed’s website. The company specializes in airway clearance therapy products, including the SmartVest Airway Clearance System, and was founded in 1992 and is headquartered in New Prague, Minnesota.
Electromed, Inc. (NYSE American: ELMD) has announced a $3.0 million stock repurchase authorization effective May 26, 2021. The company plans to buy back its common stock, with purchases made in open market transactions or through block trades. This move is driven by a strong balance sheet and positive cash flow, reflecting management's belief that the stock is undervalued. The buyback program is set to continue until May 26, 2022, but may be modified or discontinued at any time.
Electromed, Inc. (NYSE American: ELMD) has been recognized as Quality Magazine’s 2021 Plant of the Year. This accolade is based on the 2021 Quality Leadership Top 100 Company survey, which evaluates continuous improvement, quality training, warranty costs, and ISO certifications, including ISO 13485. Electromed has ranked among the top 10 in this survey three times in the last four years. CEO Kathleen Skarvan emphasized the recognition reflects the team's dedication to improving patient lives through high-quality products and services.
FAQ
What is the current stock price of Electromed (ELMD)?
What is the market cap of Electromed (ELMD)?
What does Electromed, Inc. do?
What conditions does the SmartVest® Airway Clearance System help with?
What is High-Frequency Chest Wall Oscillation (HFCWO)?
Is Electromed, Inc. certified?
What are the components of the SmartVest® System?
Where is Electromed, Inc. based?
How does the SmartVest® improve patient health?
Where can I find the latest news about Electromed, Inc.?
Does Electromed, Inc. operate worldwide?
What is the goal of Electromed, Inc.?
